Almac Group Company Updates | Glassdoor

Company Updates

  • Almac Discovery, Elasmogen and Innovate UK Collaborate to Develop VNAR Based Oncology Platform - Almac

    August 6, 2018 Craigavon, N.I., UK, 6 Aug 2018 - Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of cancer, and Elasmogen, an SME focused on the development of next generation biologics, announced today that they have been awarded a grant from Innovate UK through its Innovation in Health and Life Sciences funding programme.

  • Almac Group Launches GMP High Throughput Peptide Manufacturing Service

    July 27, 2018 Craigavon, N.I., 27 Jul 2018 - Almac Group, the global contract development and manufacturing organisation, is delighted to announce the successful MHRA registration of its High Throughput GMP Peptide manufacturing facility. Based at the Technopole campus near Edinburgh, Scotland, the facility manufactures neoantigen derived peptides for use in the production of patient specific, individualised cancer vaccines.

  • Almac Clinical Technologies Releases New Podcast Series Entitled "Spotlight on IRT: Best Practices" - Almac

    July 25, 2018 Souderton, PA - 25 July 2018 - Almac Clinical Technologies, a global leader in technology-enabled solutions for managing clinical trial patient and supplies data through its flagship IXRS® 3 Interactive Response Technology (IRT) debuts a first-in-industry podcast series entitled, "Spotlight on IRT: Best Practices."

  • Almac Group Appoints Three Vice Presidents - Almac

    Craigavon, N.I., 25 July 2018 - Almac Group, the global contract pharmaceutical development and manufacturing organisation, has announced the appointment of three new Vice Presidents within its Pharma Services Business Unit as it expands its executive team. Jonas Mortensen is appointed to the position of Vice President of Business Development.

  • Almac Group Invests in NMR Equipment to Enhance Existing Analytical Services Capability - Almac

    July 16, 2018 Craigavon, N.I., 16 July 2018 - Almac Group, the global contract development and manufacturing organisation, has announced a £375,000 investment in additional NMR instrumentation at its global Headquarters, Craigavon, UK. As part of Almac Sciences' state-of-the-art cGMP facility, enhanced NMR services will be offered to help deliver comprehensive solutions supporting drug substance (API) and drug product development programs from early phase to commercialisation.

  • "Portadown Gets Active" A summer scheme to support local children and end holiday hunger - Almac

    July 6, 2018 Children in Northern Ireland has just launched its latest "Gets Active" scheme to support local children in Portadown. The programme is being delivered in partnership with the community and voluntary sector, statutory agencies, local schools, local government and business. The "Portadown Gets Active" summer programme is about fun, learning and food.

  • Almac Discovery Appoints Dr. Xavier Jacq as Vice President, Biology - Almac

    Almac Discovery Appoints Dr. Xavier Jacq as Vice President, Biology. Xavier will be responsible for leading the company's small-molecule discovery biology team, in addition to playing a key role in defining the strategic direction of both the biology group and Almac Discovery as a whole.

  • Brexit - a seamless solution - Almac

    June 5, 2018 Timely assurance to you, our client, in relation to Brexit negotiations Download our "Brexit - a seamless solution" factsheet Download factsheet Back to news This website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies Agree

  • Almac Group turnover surpasses £500 million for first time - Almac

    June 4, 2018 Pre-tax Profits recorded at over £33M Craigavon, N.I., 4 Jun 2018 - Almac Group, the global contract pharmaceutical development and manufacturing organisation, has reported a 19% rise in revenue to £531M. The global company has also reported an increase in pre-tax profits, up from £27M in 2016 to over £33M.

  • BABCPHL Appoints George Tiger to Board of Directors

    May 29, 2018 Souderton, US, May 23, 2018 - Almac Group, the global contract pharmaceutical development and manufacturing organization, is proud to recognize the appointment of George Tiger, Vice President of Global Business Development, Almac Clinical Technologies, to the BABCPHL's Board of Directors.

Work at Almac Group? Share Your Experiences

Almac Group
  • Star
  • Star
  • Star
  • Star
  • Star
 
Click to Rate
or